Company: NGVT
Filing Date: 2025-02-19
Form Type: 10-K
Source: 0001653477-25-000015
Chunk: 550

Company: Ingevity Corp
Filing Date: 2025-02-19
Form: 10-K
Item: Item 9
Chunk 550
---
outstanding options andrestricted stock awards(A) (1)Weighted-averageexercise price ofoutstandingoptions andrestricted stockawards(B)Number of Securitiesremaining available forfuture issuance underequity compensationplans (excluding securitiesreflected in column (A))(C) (2)Equity Compensation Plans approved by stockholders988,903 $58.21 2,137,028 

_______________

(1) Includes 256,954 stock options, 499,764 restricted stock units (RSUs) and 213,117 performance-based restricted stock units (PSUs) granted to employees and 19,068 director stock units (DSUs) to be issued to directors. In accordance with SEC rules, the number of shares to be issued for performance based stock unit awards has been calculated based on the assumption that the awards granted in 2024, 2023 and 2022 will pay out at the target (1.0x).

(2) Includes 319,611 shares available for future issuance under the 2017 Ingevity Corporation Employee Stock Purchase Plan.

108

Index

ITEM 13.    CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE

The information contained in the Proxy Statement concerning our independent directors under the caption “Board and Corporate Governance Matters - Director Nominees and Selection - Director Independence” and the information contained in the Proxy Statement concerning related party transactions and our review, approval or ratification thereof appearing under the caption “Board and Corporate Governance Matters - Related Party Transactions” is incorporated herein by reference in response to this Item 13.

ITEM 14.    PRINCIPAL ACCOUNTING FEES AND SERVICES

The information contained in the Proxy Statement in the section titled “Proposal 3 - Ratification of the Appointment of Independent Registered Public Accounting Firm” is incorporated herein by reference in response to this Item 14.

109

PART IV

ITEM 15.    EXHIBIT AND FINANCIAL STATEMENT SCHEDULES

(a)Documents filed with this Report

i.Consolidated Financial Statements of Ingevity Corporation and its subsidiaries are incorporated under Item 8 of this Form 10-K.

ii.The following supplementary financial information is filed in this Form 10-K:PageFinancial Statements Schedule II – Valuation and qualifying accounts and reserves for the years ended December 31, 2024, 2023, and 2022106

All schedules have been omitted because